Table 4.
Antidepressant activity via neuroprotection a.
| CMS | Depression | |
|---|---|---|
| HPA inhibitors | ||
| CS synthesis inhibition | Kvarta et al., 2015 | Kling et al., 2009 |
| CS receptor antagonism | Wu et al., 2007 | Gallagher et al., 2008 |
| CRF antagonism | Ducottet et al., 2003 | Zobel et al., 2000 |
| Cytokine antagonism | Goshen et al., 2008 | Raison et al., 2013 |
| Oestrogen | Romano-Torres and Fernández-Guasti, 2010 | Keating et al., 2011 |
| Anti-oxidants | ||
| Omega-3 pufas | Vancassel et al., 2008 | Sarris et al., 2016 |
| Ascorbic acid | Moretti et al., 2012 | Amr et al., 2013 |
| S-adenosylmethionine | Benelli et al., 1999 | Sarris et al., 2016 |
| Melatonin | Haridas et al., 2013 | Fava et al., 2012 |
| Curcumin | Liu et al., 2014 | Sanmukhani et al., 2014 |
a
For each target the table lists a single example from each of the CMS and clinical literatures.